Richard Goodman is the technical director at GSK’s two API commercial manufacturing sites in Singapore. In this site leadership role he is responsible for the technical aspects of the sites’ manufacturing operations, including the tech transfer and validation of GSK’s small molecule New Chemical Entity (NCE) pipeline, along with process improvement programs, technical troubleshooting and lifecycle management for the sites’ established commercial products. His team also led the introduction of GSK’s first commercial API capability for both continuous manufacturing and synthetic biocatalysis, as well as the capability to manufacture highly potent APIs in a new high containment production facility.
Prior to this, Richard worked as a synthetic chemist in GSK’s R&D division outside Philadelphia, USA, where he led discovery and Quality by Design (QbD) process development of new NCE manufacturing routes for scale-up of clinical supplies and ultimately commercialization.
Richard completed his Ph.D. in Chemistry in the labs of Professor Yoshito Kishi at Harvard University in 1998, after receiving joint A.B./A.M. degrees in Chemistry from Harvard in 1992.